1.Regulation of NF-kappaB/P65 by MDM2 in acute lymphoblastic leukemia in childhood.
Qun HU ; Mu-xiang ZHOU ; Shuang-you LIU ; Liu-qing ZHANG ; Ai-quo LIU ; Yi-jie GUO ; Yu SONG
Chinese Journal of Pediatrics 2003;41(12):921-924
OBJECTIVEMDM2 is considered a proto-oncogene due to its ability to inhibit P53 tumor-suppressor function. But, evidence showed that MDM2 might have a P53-independent role in tumorigenesis. MDM2 is over-expressed in human sarcoma and carcinoma. Recent studies showed that MDM2 might act as a transcriptional factor to modulate expressions of other genes involved in cell cycle regulation and transformation. In the present study, the investigators hypothesized that MDM2 directly affected NF-kappaB expression and function in a P53-independent manner.
METHODSMDM2 was transfected to acute lymphoblastic leukemia (ALL) line EU-4 cells lacking P53 expression and expressing very low levels of MDM2. MDM2 and P65 expression in mRNA level and protein level were detected by Western blot and Northern blot after transfection. Since the expression of E-selectin is P65 dependent, E-selectin promoter-CAT construct and P65 and MDM2 expression plasmids were co-transfected to EU-4 cells. CAT activation was determined with ELISA. The effect of adriamycin (ADM) at the concentrations of 15 micro g/ml, 7.5 micro g/ml, 5 micro g/ml and 1 micro g/ml on MDM2-transfected EU-4 cells and the parent cells was detected by MTT assay.
RESULTSThe results showed that MDM2 up-regulated P65 expression at both mRNA and protein levels, and MDM2 increased P65-mediated transactivation of E-selectin promoter. Without P65, MDM2 had no effect on the transactivation of E-selectin. Moreover, MDM2 antisense could not change the transactivation of E-selectin. MTT results showed that the survival rate of MDM2 transfected EU-4 cells was higher than that of parental cells. The results suggested that MDM2 transfection increase drug resistance of EU-4 cells to ADM compared with parent cells.
CONCLUSION(1) MDM2 up-regulated transcriptionally P65 expression. (2) MDM2 increased drug resistance of leukemia cells to ADM. (3) MDM2 elevated NF-kappaB activity in a P53-independent manner in childhood lymphoblastic leukemia cell line.
Antibiotics, Antineoplastic ; therapeutic use ; Blotting, Northern ; Blotting, Western ; Cell Line, Tumor ; drug effects ; Child ; Doxorubicin ; therapeutic use ; Drug Resistance, Neoplasm ; physiology ; Enzyme-Linked Immunosorbent Assay ; Humans ; NF-kappa B ; genetics ; metabolism ; Nuclear Proteins ; genetics ; physiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; genetics ; metabolism ; pathology ; Proto-Oncogene Proteins ; genetics ; physiology ; Proto-Oncogene Proteins c-mdm2 ; RNA, Messenger ; genetics ; metabolism ; Transcription Factor RelA ; Transfection ; methods
2.Advances in the study of p53 in response to DNA damage.
Ya-Jie WANG ; Hua SUN ; Geng-Tao LIU ; Xiao-Guang CHEN
Acta Pharmaceutica Sinica 2011;46(12):1413-1419
p53 (encoded by TP53) is undoubtedly one of the most extensively studied genes and proteins. It is a highly potent transcription factor which, under normal circumstances, is maintained at low level. Both genotoxic and non-genotoxic stresses can induce p53 stabilized leading to changes in the expression of p53-responsive genes. The biological outcome inducing this pathway can be either growth arrest and apoptosis or senescence to maintain the integrity of the genome or to delete the damaged cells. The biochemical activity of p53 itself and the cellular environment govern the choice between these outcomes in a cell type- and stress-specific manner. So, p53 is a pivotal tumour suppressor and a mainstay of our body's natural anticancer defence. This review could provide some useful information for further study on the mechanisms of tumorigenesis and its progression, and also could contribute to the discovery of antitumor agents.
Animals
;
Apoptosis
;
Cell Cycle
;
Cell Line, Tumor
;
Cell Proliferation
;
DNA Damage
;
DNA Repair
;
Genes, p53
;
Humans
;
Proto-Oncogene Proteins c-mdm2
;
metabolism
;
Signal Transduction
;
Tumor Suppressor Protein p53
;
genetics
;
physiology
3.Aberrant Cell Cycle Regulation in Cervical Carcinoma.
Yonsei Medical Journal 2005;46(5):597-613
Carcinoma of the uterine cervix is one of the most common malignancies among women worldwide. Human papillomaviruses (HPV) have been identified as the major etiological factor in cervical carcinogenesis. However, the time lag between HPV infection and the diagnosis of cancer indicates that multiple steps, as well as multiple factors, may be necessary for the development of cervical cancer. The development and progression of cervical carcinoma have been shown to be dependent on various genetic and epigenetic events, especially alterations in the cell cycle checkpoint machinery. In mammalian cells, control of the cell cycle is regulated by the activity of cyclin-dependent kinases (CDKs) and their essential activating coenzymes, the cyclins. Generally, CDKs, cyclins, and CDK inhibitors function within several pathways, including the p16INK4A-cyclin D1-CDK4/6-pRb-E2F, p21WAF1-p27KIP1-cyclinE-CDK2, and p14ARF-MDM2-p53 pathways. The results from several studies showed aberrant regulation of several cell cycle proteins, such as cyclin D, cyclin E, p16 INK4A, p21WAF1, and p27KIP1, as characteristic features of HPV- infected and HPV E6/E7 oncogene-expressing cervical carcinomas and their precursors. These data suggested further that interactions of viral proteins with host cellular proteins, particularly cell cycle proteins, are involved in the activation or repression of cell cycle progression in cervical carcinogenesis.
Uterine Cervical Neoplasms/*pathology
;
Tumor Suppressor Protein p53/physiology
;
Tumor Suppressor Protein p14ARF/physiology
;
Retinoblastoma Protein/physiology
;
Proto-Oncogene Proteins c-mdm2/physiology
;
Humans
;
Female
;
E2F Transcription Factors/physiology
;
Cyclin-Dependent Kinase Inhibitor p27/physiology
;
Cyclin-Dependent Kinase Inhibitor p21/physiology
;
Cyclin-Dependent Kinase Inhibitor p16/physiology
;
Cyclin-Dependent Kinase 4/physiology
;
Cyclin-Dependent Kinase 2/physiology
;
Cyclin E/physiology
;
Cyclin D1/physiology
;
Cell Cycle/*physiology
4.Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yun YANG ; Tian XIA ; Ning LI ; Jin ZHANG ; Yuan YANG ; Wenming CONG ; Qiang DENG ; Ke LAN ; Weiping ZHOU
Protein & Cell 2013;4(1):71-81
The p53 signaling pathway works as a potent barrier to tumor progression. Two single nucleotide polymorphisms (SNPs) in the gene loci of p53 pathway, p53 codon 72 Arg72Pro and MDM2 SNP309 (T > G), have been shown to cause perturbation of p53 function, but the effect of the two SNPs on the risk of hepatocellular carcinoma (HCC) remains inconsistent. This study investigated the influence of combined p53 Arg72Pro and MDM2 SNP309 on the risk of developing HCC in patients with chronic hepatitis B virus infection, and evaluated the significance of the two combined SNPs on patient prognosis. In total, 350 HCC patients, 230 non-HCC patients, and 96 healthy controls were genotyped for the p53 Arg72Pro and MDM2 SNP309. The combined p53 Pro/Pro and MDM2 G/G genotype was significantly associated with HCC risk (P = 0.047). Multivariate analysis indicated that combined p53 Pro/Pro and MDM2 G/G genotype was an independent factor affecting recurrence and survival (P < 0.05). Patients with combined p53 Pro/Pro and MDM2 G/G genotypes had a poorer prognosis than other genotypes, P < 0.01 for both disease-free survival (DFS) and overall survival (OS). DFS and OS rates also differed significantly between Barcelona Clinic Liver Cancer (BCLC) stage A patients with combined p53 Pro/Pro and MDM2 G/G and other genotypes (P < 0.05). Thus, the combined p53 Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC.
Carcinoma, Hepatocellular
;
diagnosis
;
genetics
;
surgery
;
virology
;
Carrier State
;
virology
;
Cohort Studies
;
Female
;
Genetic Predisposition to Disease
;
genetics
;
Hepatitis B virus
;
physiology
;
Humans
;
Liver Neoplasms
;
diagnosis
;
genetics
;
surgery
;
virology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Polymorphism, Single Nucleotide
;
Prognosis
;
Proto-Oncogene Proteins c-mdm2
;
genetics
;
Tumor Suppressor Protein p53
;
genetics
5.Novel natural product therapeutics targeting both inflammation and cancer.
Jiangjiang QIN ; Wei WANG ; Ruiwen ZHANG
Chinese Journal of Natural Medicines (English Ed.) 2017;15(6):401-416
Inflammation is recently recognized as one of the hallmarks of human cancer. Chronic inflammatory response plays a critical role in cancer development, progression, metastasis, and resistance to chemotherapy. Conversely, the oncogenic aberrations also generate an inflammatory microenvironment, enabling the development and progression of cancer. The molecular mechanisms of action that are responsible for inflammatory cancer and cancer-associated inflammation are not fully understood due to the complex crosstalk between oncogenic and pro-inflammatory genes. However, molecular mediators that regulate both inflammation and cancer, such as NF-κB and STAT have been considered as promising targets for preventing and treating these diseases. Recent works have further demonstrated an important role of oncogenes (e.g., NFAT1, MDM2) and tumor suppressor genes (e.g., p53) in cancer-related inflammation. Natural products that target these molecular mediators have shown anticancer and anti-inflammatory activities in preclinical and clinical studies. Sesquiterpenoids (STs), a class of novel plant-derived secondary metabolites have attracted great interest in recent years because of their diversity in chemical structures and pharmacological activities. At present, we and other investigators have found that dimeric sesquiterpenoids (DSTs) may exert enhanced activity and binding affinity to molecular targets due to the increased number of alkylating centers and improved conformational flexibility and lipophilicity. Here, we focus our discussion on the activities and mechanisms of action of STs and DSTs in treating inflammation and cancer as well as their structure-activity relationships.
Animals
;
Anti-Inflammatory Agents
;
pharmacology
;
Antineoplastic Agents, Phytogenic
;
pharmacology
;
Humans
;
Inflammation
;
drug therapy
;
etiology
;
NF-kappa B
;
antagonists & inhibitors
;
NFATC Transcription Factors
;
antagonists & inhibitors
;
Neoplasms
;
drug therapy
;
etiology
;
Proto-Oncogene Proteins c-mdm2
;
antagonists & inhibitors
;
physiology
;
Sesquiterpenes
;
chemistry
;
pharmacology
;
Structure-Activity Relationship